

Complete remission with immunotherapy: Case report of a ...

<https://www.ncbi.nlm.nih.gov/pubmed/32123665>

Feb 12, 2020 · Bladder cancer is the sixth most common malignancy in the United States. Cisplatin combination regimens are first line therapy for patients with metastatic urothelial bladder cancer who are eligible candidates and no treatments have shown to improve outcome compared to chemotherapy for the past 20 years.

Author: D. Abdelhakam, P.R. Young, M.K. Jai... Publish Year: 2020

Complete response to trastuzumab and chemotherapy in ...

<https://pubmed.ncbi.nlm.nih.gov/32110671>

A phase II trial has explored the combination of cytotoxic chemotherapy with the anti-HER-2 monoclonal antibody trastuzumab in selected patients with metastatic bladder cancer, but it failed. Case summary: Here, we report a case of recurrent urothelial bladder carcinoma (UBC) in a patient who has undergone three operations, and further ...

PEOPLE ALSO ASK

How does the size of bladder cancer affect treatment? ▾

What is the new immunotherapy for bladder cancer? ▾

Which is better intravesical BCG or chemotherapy for bladder cancer? ▾

What is the treatment for recurrent bladder cancer? ▾

Feedback

Primary metastatic neuroendocrine small cell bladder ...

<https://pubmed.ncbi.nlm.nih.gov/22236613>

Small cell cancer, rarely found in the urogenital tract in a primitive form, usually coexists with urothelial bladder cancers. It has an incidence of 0.35-0.7% of all bladder neoplasms and survival at 5 years is estimated to be around 8%.

[PDF] Metastatic non-muscle invasive bladder cancer with ...

<https://bmccancer.biomedcentral.com/track/pdf/10...>

ALL

IMAGES

VIDEOS

68,900 Results

Any time ▾

Primary metastatic neuroendocrine small cell bladder ...

<https://pubmed.ncbi.nlm.nih.gov/22236613>

Small cell cancer, rarely found in the urogenital tract in a primitive form, usually coexists with urothelial bladder cancers. It has an incidence of 0.35-0.7% of all bladder neoplasms and survival at 5 years is...

Cited by: 4

Author: C Cerulli, G M Busetto, G Antonini, R Giovan...

Publish Year: 2012

Case report: complete response of metastatic transitional ...

<https://www.ncbi.nlm.nih.gov/pubmed/6538239>

Case report: complete response of metastatic transitional cell carcinoma of the bladder with chemotherapy alone. Dougherty WE, Lynch JH, Maxted WC. Transitional cell carcinoma of the bladder h...

PEOPLE ALSO ASK

How does the size of bladder cancer affect treatment? ▾

What is the treatment for recurrent bladder cancer? ▾

Can bladder cancer cause squamous cell carcinoma? ▾

Which is the best treatment for Stage 3 bladder cancer? ▾

[Feedback](#)

Metastatic non-muscle invasive bladder cancer with ...

<https://pubmed.ncbi.nlm.nih.gov/28494780>

国内版

国际版

Successful response to camrelizumab in metastatic bladder cancer:



ALL

IMAGES

VIDEOS

78,900 Results

Any time ▾

Successful treatment of advanced alveolar soft part ...

<https://pubmed.ncbi.nlm.nih.gov/33545800>

Radiotherapy was administered in addition to camrelizumab combined with apatinib to treat the brain metastases. The patient achieved partial remission (46%) after 3 months of treatment and did not present any severe side effects. This is the first reported case of the successful treatment of advanced ASPS with camrelizumab combined with apatinib.

Cited by: 1

Author: Zhen Xu, Yong Zhang, Yong-Hua Yu

Publish Year: 2021

Case Report: Significant Response to Immune Checkpoint ...

<https://pubmed.ncbi.nlm.nih.gov/33634015>

Here we present a case of an ER+/HER2- but TMB-high mBC patient who had significant response to combination therapy with anti-PD-1 antibody camrelizumab and vinorelbine and obtained partial response (PR) with a progression-free survival (PFS) of 5 months after failure of multiple lines of therapy.

Author: Rong Wang, Yuchen Yang, Wei-Wu Y...

Publish Year: 2021

PEOPLE ALSO ASK

How did pembrolizumab get approved for bladder cancer?



What are the side effects of durvalumab in bladder cancer?



How is the treatment of bladder cancer determined?



What are the side effects of immunotherapy for bladder cancer?



Feedback

Successful treatment of advanced alveolar soft part ...

<https://apm.amegroups.com/article/view/61583/html> ▾

This is a case report of a 32-year-old male with advanced ASPS and multiple organ metastases who showed a strong response to treatment with the combination of camrelizumab plus apatinib. Follow-up imaging after six treatment cycles revealed that both the primary tumor and metastatic lesions ...

Cited by: 1

Author: Zhen Xu, Yong Zhang, Yong-Hua Yu